<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="0" ids="31882">N-methyl-D-aspartate</z:chebi> receptor <z:chebi fb="68" ids="48706">antagonists</z:chebi> are potent neuroprotectants in experimental focal <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo>, but behavioral and neuropathologic changes seen with these drugs in <z:e sem="disease" ids="C1519106" disease_type="Experimental Model of Disease" abbrv="">rodent models</z:e> may limit the clinical utility of these compounds </plain></SENT>
<SENT sid="1" pm="."><plain>Glycine's modulation of <z:chebi fb="0" ids="31882">N-methyl-D-aspartate</z:chebi> channel function offers another pharmacologic approach to excitotoxicity in <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>The potent glycine <z:chebi fb="68" ids="48706">antagonist</z:chebi> 7 Chlorothiokynurenic acid (7-Cl-<z:chebi fb="1" ids="29830">Thio</z:chebi>-Kyna) was studied in a permanent middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> <z:hpo ids='HP_0001297'>stroke</z:hpo> model in the rat </plain></SENT>
<SENT sid="3" pm="."><plain>The compound was effective, in a dose-dependent manner, in attenuating <z:mpath ids='MPATH_124'>infarct</z:mpath> size when administered before or after permanent middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> </plain></SENT>
<SENT sid="4" pm="."><plain>Its activity was mainly due to glycine antagonism inasmuch as 5 Chlorothiokynurenic acid, a compound having other pharmacological activities in common with 7-CI-<z:chebi fb="1" ids="29830">Thio</z:chebi>-Kyna (for instance the radical scavenger action), was inactive in this model </plain></SENT>
<SENT sid="5" pm="."><plain>7-Cl-<z:chebi fb="1" ids="29830">Thio</z:chebi>-Kyna did not produce cytological changes similar to MK 801 </plain></SENT>
</text></document>